JP2022166140A5 - - Google Patents

Download PDF

Info

Publication number
JP2022166140A5
JP2022166140A5 JP2022127059A JP2022127059A JP2022166140A5 JP 2022166140 A5 JP2022166140 A5 JP 2022166140A5 JP 2022127059 A JP2022127059 A JP 2022127059A JP 2022127059 A JP2022127059 A JP 2022127059A JP 2022166140 A5 JP2022166140 A5 JP 2022166140A5
Authority
JP
Japan
Prior art keywords
seq
amino acid
cancer
domain
acid substitution
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2022127059A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022166140A (ja
JP7402556B2 (ja
Filing date
Publication date
Priority claimed from JP2020002993A external-priority patent/JP2020073569A/ja
Application filed filed Critical
Publication of JP2022166140A publication Critical patent/JP2022166140A/ja
Publication of JP2022166140A5 publication Critical patent/JP2022166140A5/ja
Application granted granted Critical
Publication of JP7402556B2 publication Critical patent/JP7402556B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2022127059A 2014-01-27 2022-08-09 哺乳動物への応用のための脱免疫化された志賀毒素aサブユニットエフェクターポリペプチド Active JP7402556B2 (ja)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US201461932000P 2014-01-27 2014-01-27
US61/932,000 2014-01-27
US201462049325P 2014-09-11 2014-09-11
US62/049,325 2014-09-11
JP2020002993A JP2020073569A (ja) 2014-01-27 2020-01-10 哺乳動物への応用のための脱免疫化された志賀毒素aサブユニットエフェクターポリペプチド
JP2021102325A JP7126729B2 (ja) 2014-01-27 2021-06-21 哺乳動物への応用のための脱免疫化された志賀毒素aサブユニットエフェクターポリペプチド

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2021102325A Division JP7126729B2 (ja) 2014-01-27 2021-06-21 哺乳動物への応用のための脱免疫化された志賀毒素aサブユニットエフェクターポリペプチド

Publications (3)

Publication Number Publication Date
JP2022166140A JP2022166140A (ja) 2022-11-01
JP2022166140A5 true JP2022166140A5 (cg-RX-API-DMAC7.html) 2022-11-09
JP7402556B2 JP7402556B2 (ja) 2023-12-21

Family

ID=52469328

Family Applications (8)

Application Number Title Priority Date Filing Date
JP2016546493A Active JP6646584B2 (ja) 2014-01-27 2015-01-26 哺乳動物への応用のための脱免疫化された志賀毒素aサブユニットエフェクターポリペプチド
JP2016546476A Active JP6655017B2 (ja) 2014-01-27 2015-01-26 Mhcクラスiエピトープ送達ポリペプチド
JP2020002993A Pending JP2020073569A (ja) 2014-01-27 2020-01-10 哺乳動物への応用のための脱免疫化された志賀毒素aサブユニットエフェクターポリペプチド
JP2020014954A Pending JP2020079267A (ja) 2014-01-27 2020-01-31 Mhcクラスiエピトープ送達ポリペプチド
JP2021092504A Active JP7229570B2 (ja) 2014-01-27 2021-06-01 Mhcクラスiエピトープ送達ポリペプチド
JP2021102325A Expired - Fee Related JP7126729B2 (ja) 2014-01-27 2021-06-21 哺乳動物への応用のための脱免疫化された志賀毒素aサブユニットエフェクターポリペプチド
JP2022127059A Active JP7402556B2 (ja) 2014-01-27 2022-08-09 哺乳動物への応用のための脱免疫化された志賀毒素aサブユニットエフェクターポリペプチド
JP2023016832A Active JP7442879B2 (ja) 2014-01-27 2023-02-07 Mhcクラスiエピトープ送達ポリペプチド

Family Applications Before (6)

Application Number Title Priority Date Filing Date
JP2016546493A Active JP6646584B2 (ja) 2014-01-27 2015-01-26 哺乳動物への応用のための脱免疫化された志賀毒素aサブユニットエフェクターポリペプチド
JP2016546476A Active JP6655017B2 (ja) 2014-01-27 2015-01-26 Mhcクラスiエピトープ送達ポリペプチド
JP2020002993A Pending JP2020073569A (ja) 2014-01-27 2020-01-10 哺乳動物への応用のための脱免疫化された志賀毒素aサブユニットエフェクターポリペプチド
JP2020014954A Pending JP2020079267A (ja) 2014-01-27 2020-01-31 Mhcクラスiエピトープ送達ポリペプチド
JP2021092504A Active JP7229570B2 (ja) 2014-01-27 2021-06-01 Mhcクラスiエピトープ送達ポリペプチド
JP2021102325A Expired - Fee Related JP7126729B2 (ja) 2014-01-27 2021-06-21 哺乳動物への応用のための脱免疫化された志賀毒素aサブユニットエフェクターポリペプチド

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2023016832A Active JP7442879B2 (ja) 2014-01-27 2023-02-07 Mhcクラスiエピトープ送達ポリペプチド

Country Status (11)

Country Link
US (8) US20160347798A1 (cg-RX-API-DMAC7.html)
EP (4) EP3868776A1 (cg-RX-API-DMAC7.html)
JP (8) JP6646584B2 (cg-RX-API-DMAC7.html)
KR (6) KR102514910B1 (cg-RX-API-DMAC7.html)
CN (4) CN111909278B (cg-RX-API-DMAC7.html)
AU (8) AU2015209063C1 (cg-RX-API-DMAC7.html)
CA (1) CA2937407A1 (cg-RX-API-DMAC7.html)
ES (2) ES2749862T3 (cg-RX-API-DMAC7.html)
IL (8) IL294746B2 (cg-RX-API-DMAC7.html)
MX (4) MX382229B (cg-RX-API-DMAC7.html)
WO (2) WO2015113005A1 (cg-RX-API-DMAC7.html)

Families Citing this family (47)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2011302645B2 (en) 2010-09-15 2015-02-26 Applied Molecular Transport, Llc Systems and methods of delivery of bioactive agents using bacterial toxin-derived transport sequences
US11246915B2 (en) 2010-09-15 2022-02-15 Applied Molecular Transport Inc. Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
EP2639299A1 (en) 2012-03-16 2013-09-18 Invectys Universal cancer peptides derived from telomerase
CN111363047A (zh) 2013-03-12 2020-07-03 分子模板公司 用于引起细胞内化的cd20结合免疫毒素及其使用方法
CA2908138A1 (en) 2013-03-28 2014-10-02 Invectys A cancer vaccine for cats
AU2014242916B2 (en) 2013-03-28 2018-08-02 Invectys A cancer vaccine for dogs
EP3063280B1 (en) 2013-10-28 2019-08-14 Invectys Gene electrotransfer into skin cells
HUE047898T2 (hu) 2013-10-28 2020-05-28 Invectys Telomerázt kódoló DNS vakcina
ES2749862T3 (es) 2014-01-27 2020-03-24 Molecular Templates Inc Polipéptidos efectores desinmunizados de subunidad A de toxina Shiga para aplicaciones en mamíferos
US11142584B2 (en) 2014-03-11 2021-10-12 Molecular Templates, Inc. CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using same
ES2864124T3 (es) * 2014-03-11 2021-10-13 Molecular Templates Inc Proteínas que comprenden regiones de unión, regiones efectoras de la subunidad A de toxina Shiga y motivos señal de localización de retículo endoplasmático carboxi terminal
EP3139965B1 (en) 2014-05-07 2021-09-29 Applied Molecular Transport Inc. Cholix toxin-derived fusion molecules for oral delivery of biologically active cargo
KR102496206B1 (ko) 2014-06-11 2023-02-06 몰레큘러 템플레이츠, 인코퍼레이션. 프로테아제-절단 저항성의 시가 독소 a 서브유닛 작동체 폴리펩티드 및 이를 포함하는 세포-표적화 분자
WO2016126950A1 (en) 2015-02-05 2016-08-11 Molecular Templates, Inc. Multivalent cd20-binding molecules comprising shiga toxin a subunit effector regions and enriched compositions thereof
CN114656573B (zh) 2015-05-30 2024-09-27 分子模板公司 去免疫化的志贺毒素a亚基支架和包含它们的细胞靶向分子
MX2018001208A (es) 2015-07-26 2018-03-26 Molecular Templates Inc Moleculas con direccion a las celulas que comprenden efectores de la subunidad a de la toxina shiga y epitopos de celulas-t cd8+.
WO2017059270A1 (en) * 2015-10-02 2017-04-06 Regents Of The University Of Minnesota Deimmunized therapeutic compositions and methods
JP7114477B2 (ja) * 2015-12-16 2022-08-08 グリットストーン バイオ インコーポレイテッド 新生抗原の特定、製造、および使用
WO2017195508A1 (ja) * 2016-05-09 2017-11-16 信越化学工業株式会社 室温硬化性オルガノポリシロキサン組成物及び該組成物の硬化物でコーティングされた基材
MX2019006656A (es) 2016-12-07 2019-09-09 Molecular Templates Inc Polipeptidos efectores de la sub-unidad a de la toxina shiga andamiajes de los efectores de la toxina shiga y moleculas con direccion hacia las celulas para la conjugacion especifica del sitio.
KR102590672B1 (ko) 2017-01-25 2023-10-18 몰레큘러 템플레이츠, 인코퍼레이션. 탈면역된 시가 독소 a 서브유닛 이펙터 및 cd8+ t-세포 에피토프를 포함하는 세포-표적화 분자
JP2020517692A (ja) * 2017-04-27 2020-06-18 イミュソフト コーポレーション 治療剤のin vivo送達のためのB細胞およびその投薬量
EP3622078A1 (en) 2017-05-09 2020-03-18 Invectys Recombinant measles vaccine expressing htert
CN111201030B (zh) 2017-07-25 2024-11-01 真和制药有限公司 通过阻断tim-3和其配体的相互作用治疗癌症
CN111465989B (zh) 2017-10-10 2024-06-25 磨石生物公司 使用热点进行的新抗原鉴别
AU2018373154B2 (en) 2017-11-22 2025-08-07 Seattle Project Corp. Reducing junction epitope presentation for neoantigens
CN111836635A (zh) * 2018-01-26 2020-10-27 剑桥企业有限公司 肽交换蛋白
PL3762009T3 (pl) 2018-03-08 2022-09-12 Applied Molecular Transport Inc. Pochodzące z toksyny konstrukty dostarczające do dostarczania doustnego
KR20200143634A (ko) * 2018-04-17 2020-12-24 몰레큘러 템플레이츠, 인코퍼레이션. 탈면역된 시가 독소 a 서브유닛 스캐폴드를 포함하는 her2-표적화 분자
WO2020081493A1 (en) 2018-10-16 2020-04-23 Molecular Templates, Inc. Pd-l1 binding proteins
CN109504683A (zh) * 2018-11-13 2019-03-22 广西壮族自治区水产科学研究院 罗非鱼的半乳糖凝集素-3基因序列及其克隆方法
US11414496B2 (en) 2019-01-23 2022-08-16 Takeda Pharmaceutical Company Limited Anti-CD38 binding domains
US11713347B2 (en) 2019-01-23 2023-08-01 Millennium Pharmaceuticals, Inc. CD38-binding proteins comprising de-immunized Shiga toxin A subunit effectors
WO2020154475A1 (en) 2019-01-23 2020-07-30 Molecular Templates, Inc. Proteins comprising modified immunoglobulin variable light chains
KR20210124308A (ko) 2019-01-30 2021-10-14 트루바인딩 아이엔씨. 항-gal3 항체 및 이의 용도
JP2022542867A (ja) * 2019-07-23 2022-10-07 ドイチェス クレブスフォルシュンクスツェントルム Amlの処置のためのポリペプチド
GB201910605D0 (en) * 2019-07-24 2019-09-04 Immetacyte Ltd Tumour infltracting lymphocyte therapy amd uses thereo
MX2022001975A (es) 2019-08-16 2022-03-11 Applied Molecular Transport Inc Composiciones, formulaciones y produccion y purificacion de interleucinas.
WO2021055816A1 (en) 2019-09-18 2021-03-25 Molecular Templates, Inc. Pd-l1 binding molecules comprising shiga toxin a subunit scaffolds
US20210155671A1 (en) 2019-11-24 2021-05-27 Molecular Templates, Inc. Uses of cd20-binding molecules and additional therapeutic agents
MX2022014786A (es) 2020-05-26 2023-01-16 Truebinding Inc Metodos para tratar enfermedades inflamatorias mediante el bloqueo de galectina-3.
CN113621030B (zh) * 2020-07-14 2023-05-26 上海科技大学 一种诱导蛋白质降解的多肽及其应用
EP4262858A1 (en) 2020-12-16 2023-10-25 Molecular Templates, Inc. Clinical methods for use of a pd-l1-binding molecule comprising a shiga toxin effector
US20220306700A1 (en) 2021-03-17 2022-09-29 Molecular Templates, Inc. Pd-l1 binding proteins comprising shiga toxin a subunit scaffolds and cd8+ t cell antigens
AU2023230954A1 (en) * 2022-03-08 2024-10-17 Molecular Templates, Inc. Ctla-4 binding molecules comprising shiga toxin a subunit scaffolds and uses thereof
JP2026511877A (ja) * 2023-03-31 2026-04-14 康碼(上海)生物科技有限公司 融合タンパク質と対応する核酸、インビトロ合成系及び製造方法
CN116554300B (zh) * 2023-04-27 2023-10-24 湖北医药学院 一种能与艰难拟梭菌毒素TcdB相互作用的多肽及其应用

Family Cites Families (134)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5080898A (en) 1982-05-12 1992-01-14 The University Hospital Enzymatically active toxin coupled to a cell-specific ligand
US4894443A (en) 1984-02-08 1990-01-16 Cetus Corporation Toxin conjugates
US5668255A (en) 1984-06-07 1997-09-16 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
US6022950A (en) 1984-06-07 2000-02-08 Seragen, Inc. Hybrid molecules having translocation region and cell-binding region
US5091178A (en) 1986-02-21 1992-02-25 Oncogen Tumor therapy with biologically active anti-tumor antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5135736A (en) 1988-08-15 1992-08-04 Neorx Corporation Covalently-linked complexes and methods for enhanced cytotoxicity and imaging
AU657087B2 (en) 1989-12-22 1995-03-02 Seragen Incorporated Hybrid molecules having translocation region and cell-binding region
US5635384A (en) 1990-06-11 1997-06-03 Dowelanco Ribosome-inactivating proteins, inactive precursor forms thereof, a process for making and a method of using
US5621083A (en) 1991-11-04 1997-04-15 Xoma Corporation Immunotoxins comprising ribosome-inactivating proteins
US6146850A (en) 1991-11-04 2000-11-14 Xoma Corporation Proteins encoding gelonin sequences
US5552144A (en) 1992-01-22 1996-09-03 Microcarb, Inc. Immunogenic shiga-like toxin II variant mutants
AU6912294A (en) 1993-05-12 1994-12-12 Xoma Corporation Immunotoxins comprising ribosome-inactivating proteins
US5612474A (en) 1994-06-30 1997-03-18 Eli Lilly And Company Acid labile immunoconjugate intermediates
AU3374795A (en) 1994-08-29 1996-03-22 Prizm Pharmaceuticals, Inc. Conjugates of vascular endothelial growth factor with targeted agents
CA2218601A1 (en) 1995-03-24 1996-10-03 Ophidian Pharmaceuticals, Inc. Treatment for verotoxin-producing escherichia coli
US5667786A (en) 1995-06-07 1997-09-16 Novavax, Inc. Method for treating tumors with a toxin
US5858682A (en) 1996-08-02 1999-01-12 Pharmingen E2A/pbx1 fusion protein specific monoclonal antibodies
CZ295838B6 (cs) 1996-09-09 2005-11-16 Zealand Pharma A/S Způsob výroby peptidů
CA2265887A1 (en) 1996-09-10 1998-03-19 Henry M. Jackson Foundation For The Advancement Of Military Medicine Histidine-tagged shiga toxins, toxoids, and protein fusions with such toxins and toxoids, methods for the purification and preparation thereof
US6306393B1 (en) 1997-03-24 2001-10-23 Immunomedics, Inc. Immunotherapy of B-cell malignancies using anti-CD22 antibodies
FR2766193B1 (fr) 1997-07-18 2001-09-14 Inst Curie Polypeptide chimerique comprenant le fragment b de la toxine shiga et des peptides d'interet therapeutique
CA2222993A1 (en) 1998-02-04 1999-08-04 The Ontario Cancer Institute A method for using a ribosome-inactivating protein complex as a structural template and a molecular search engine in the design, construction and screening of combinatorial protein libraries
AU770718B2 (en) 1998-06-05 2004-02-26 Mayo Foundation For Medical Education And Research Use of genetically engineered antibodies to CD38 to treat multiple myeloma
WO2000004926A2 (en) 1998-07-22 2000-02-03 Osprey Pharmaceuticals Limited Conjugates for treating inflammatory disorders and associated tissue damage
US7157418B1 (en) 1998-07-22 2007-01-02 Osprey Pharmaceuticals, Ltd. Methods and compositions for treating secondary tissue damage and other inflammatory conditions and disorders
AU2004202331A1 (en) 1998-07-22 2004-06-24 Osprey Pharmaceuticals Limited Methods and Compositions for Treating Secondary Tissue Damage and Other Inflammatory Conditions and Disorders
US6770456B1 (en) 1998-07-29 2004-08-03 Ludwig Institute For Cancer Research Endogenous retrovirus tumor associated nucleic acids and antigens
ES2313886T3 (es) 1999-03-16 2009-03-16 The Government Of The Usa, As Represented By The Secretary, Department Of Health And Human Services Nueva proteina quimerica para la prevencion y tratamiento de infeccion por hiv.
US7527787B2 (en) 2005-10-19 2009-05-05 Ibc Pharmaceuticals, Inc. Multivalent immunoglobulin-based bioactive assemblies
US7144991B2 (en) 1999-06-07 2006-12-05 Aletheon Pharmaceuticals, Inc. Streptavidin expressed gene fusions and methods of use thereof
US6492498B1 (en) 1999-11-15 2002-12-10 Regents Of The University Of Minnesota Multimeric immunotoxins
US7267973B2 (en) 2000-03-22 2007-09-11 Sibtech, Inc. Nucleic acids encoding recombinant proteins containing Shiga-like toxin and vascular endothelial growth factor
US20010031485A1 (en) * 2000-03-22 2001-10-18 Sibtech, Inc. Recombinant proteins containing Shiga-like toxin and vascular endothelial growth factor fragments
PT2857516T (pt) 2000-04-11 2017-08-28 Genentech Inc Anticorpos multivalentes e utilizações dos mesmos
US20020127247A1 (en) 2000-11-17 2002-09-12 Allergen Sales, Inc. Modified clostridial neurotoxins with altered biological persistence
US7829084B2 (en) 2001-01-17 2010-11-09 Trubion Pharmaceuticals, Inc. Binding constructs and methods for use thereof
WO2003066854A1 (fr) 2002-02-04 2003-08-14 Yoshida, Hideo Agent anticancereux utilisant des variantes de verotoxines
JP4597528B2 (ja) 2002-02-26 2010-12-15 ジェネンコー・インターナショナル・インク 免疫原性が減少したズブチリシン・カールスバーグタンパク質
KR101017732B1 (ko) 2002-03-01 2011-02-28 이뮤노메딕스, 인코오포레이티드 내재화 항-cd74 항체 및 그 이용방법
ATE292144T1 (de) 2002-08-02 2005-04-15 Inst Curie Shiga-toxin-untereinheit b als vektor zur diagnose von tumoren und zur arzneimittelverabreichung an gb3-exprimierenden tumoren
HUE035898T2 (en) 2002-12-16 2018-05-28 Genentech Inc Immunoglobulin variants and their applications
WO2004058158A2 (en) 2002-12-20 2004-07-15 The Johns Hopkins University Treatment of metastatic cancer with the b-subunit of shiga toxin
US7834258B2 (en) 2003-06-30 2010-11-16 Mu-Hyeon Choe Dimer of chimeric recombinant binding domain-functional group fusion formed via disulfide-bond-bridge and the processes for producing the same
US8147832B2 (en) 2003-08-14 2012-04-03 Merck Patent Gmbh CD20-binding polypeptide compositions and methods
US7585942B2 (en) 2003-11-25 2009-09-08 Anjin Corporation Diphtheria toxin variant
DE602004027291D1 (de) 2003-11-25 2010-07-01 Us Gov Health & Human Serv Mutierte anti-cd22-antikörper und immunkonjugate
MXPA06008700A (es) 2004-02-06 2007-01-19 Morphosys Ag Anticuerpos anti-cd38 humanos y usos para los mismos.
ATE467641T1 (de) 2004-03-26 2010-05-15 Molecular Templates Inc Bibliothek von toxin mutanten und deren verwendung
US8858930B2 (en) * 2004-10-26 2014-10-14 Chengru Zhu Live attenuated bacterial vaccine to reduce or inhibit carriage and shedding of enterohemorrhagic Escherichia coli in cattle
EP2551282A3 (en) 2005-03-23 2013-02-13 Genmab A/S Antibodies against CD38 for treatment of multiple myeloma
KR101704734B1 (ko) 2005-07-01 2017-02-09 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
FI20055417A0 (fi) 2005-07-20 2005-07-20 Glykos Finland Oy Syöpäpesifiset glykaanit ja niiden käyttö
WO2007014238A2 (en) 2005-07-25 2007-02-01 Trubion Pharmaceuticals, Inc. Single dose use of cd20-specific binding molecules
AU2006279541A1 (en) 2005-08-15 2007-02-22 The Regents Of The University Of California VEGF-activated FAS ligands
CA2664549A1 (en) * 2005-09-26 2007-03-29 University Health Network Library from toxin mutants, and methods of using same
GB0524788D0 (en) 2005-12-05 2006-01-11 Affibody Ab Polypeptides
WO2007071061A1 (en) 2005-12-23 2007-06-28 Viventia Biotech Inc. Methods for generating and screening fusion protein libraries and uses thereof
EP1991565B1 (en) 2006-02-16 2015-01-21 The Henry M. Jackson Foundation for the Advancement of Military Medicine, Inc. Shiga toxoid chimeric proteins
US7373982B2 (en) 2006-03-21 2008-05-20 Halliburton Energy Services, Inc. Cements for use across formations containing gas hydrates
WO2008073160A2 (en) 2006-08-17 2008-06-19 The Trustees Of Columbia University In The City Of New York Methods for converting or inducing protective immunity
JP4954293B2 (ja) 2006-12-29 2012-06-13 オスプレイ・ファーマシューティカルズ・ユーエスエイ・インコーポレイテッド 改変毒素を選択および生産する方法、改変毒素を含む複合体、およびそれらの使用
CN101622352A (zh) * 2006-12-29 2010-01-06 美国奥斯普瑞医药公司 选择和产生修饰的毒素、含有修饰的毒素的缀合物的方法及其应用
EP2684889A3 (en) 2007-02-02 2014-03-05 Baylor Research Institute Multivariable antigens complexed with targeting humanized monoclonal antibody
GB2456904B8 (en) * 2007-03-22 2009-12-09 Heptares Therapeutics Ltd Stable neurotensin receptor mutants
US20090010966A1 (en) 2007-06-21 2009-01-08 Angelica Therapeutics, Inc. Modified diphtheria toxins
US7887801B2 (en) 2007-07-13 2011-02-15 Topotarget Germany Ag Optimized DNA and protein sequence of an antibody to improve quality and yield of bacterially expressed antibody fusion proteins
US9364557B2 (en) 2007-08-01 2016-06-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Fold-back diabody diphtheria toxin immunotoxin and methods of use
DK2197903T3 (en) 2007-09-04 2015-01-05 Us Gov Health & Human Serv Deletions in Domain II from Pseudomonas exotoxin A that reduce non-specific TOXICITY
US20100298238A1 (en) 2007-10-08 2010-11-25 Rutgers, The State University Nontoxic shiga-like toxin mutant compositions and methods
EP2048896B1 (en) 2007-10-12 2011-12-21 STMicroelectronics Srl Method and circuit for testing an audio high-frequency loudspeaker being part of a loudspeaker system
US20090148904A1 (en) 2007-11-13 2009-06-11 Mayfield Stephen P Production of cytotoxic antibody-toxin fusion in eukaryotic algae
CA2706425A1 (en) 2007-11-27 2009-06-04 Ablynx N.V. Method for obtaining polypeptide constructs comprising two or more single domain antibodies
WO2009078766A1 (en) 2007-12-17 2009-06-25 Telefonaktiebolaget Lm Ericsson (Publ) Multi-antenna receiver interference cancellation method and apparatus
EP2268297A4 (en) 2008-02-29 2011-11-16 Angelica Therapeutics Inc MODIFIED TOXINS
CN101629158A (zh) * 2008-07-17 2010-01-20 冯书章 出血性大肠杆菌o157重组疫苗
CN102159243B (zh) 2008-07-21 2015-08-19 免疫医疗公司 用于改良的治疗特征的抗体的结构变体
AU2009293640A1 (en) 2008-09-22 2010-03-25 Calmune Corporation Methods and vectors for display of 2G12 -derived domain exchanged antibodies
US8147847B2 (en) * 2008-10-21 2012-04-03 International Vaccine Institute Shigella protein antigens and methods
US8969529B2 (en) 2009-01-23 2015-03-03 The Henry M. Jackson Foundation For The Advancement Of Military Medicine, Inc. Methods and compositions based on shiga toxin type 2 protein
US9034341B2 (en) 2009-04-20 2015-05-19 Transtech Pharma, Llc Control of RAGE fusion protein glycosylation and RAGE fusion protein compositions
EP2456470A1 (en) 2009-07-22 2012-05-30 Cenix Bioscience GmbH Delivery system and conjugates for compound delivery via naturally occurring intracellular transport routes
US9174169B2 (en) 2009-08-14 2015-11-03 Unifrax I Llc Mounting mat for exhaust gas treatment device
EP2371864A1 (en) 2010-03-23 2011-10-05 Ganymed Pharmaceuticals AG Monoclonal antibodies for treatment of cancer
IL299365A (en) 2010-05-27 2023-02-01 Genmab As Monoclonal antibodies against 2HER
GB201013989D0 (en) 2010-08-20 2010-10-06 Univ Southampton Biological materials and methods of using the same
US9321847B2 (en) 2010-09-20 2016-04-26 Ramot At Tel Aviv University Ltd. Activatable toxin complexes comprising a cleavable inhibitory peptide
PL219845B1 (pl) 2011-01-05 2015-07-31 Adamed Spółka Z Ograniczoną Odpowiedzialnością Przeciwnowotworowe białko fuzyjne
EP2476441A1 (en) * 2011-01-13 2012-07-18 Universitat Autònoma De Barcelona Methods and reagents for efficient and targeted delivery of therapeutic molecules to CXCR4 cells
WO2012101235A1 (en) 2011-01-26 2012-08-02 Cenix Bioscience Gmbh Delivery system and conjugates for compound delivery via naturally occurring intracellular transport routes
SG191977A1 (en) 2011-02-01 2013-08-30 Genmab As Human antibodies and antibody-drug conjugates against cd74
US20140088019A1 (en) 2011-02-11 2014-03-27 Zyngenia, Inc. Monovalent and Multivalent Multispecific Complexes and Uses Thereof
US8895006B2 (en) * 2011-03-04 2014-11-25 Rutgers, The State University Of New Jersey Ricin ribosome binding protein compositions and methods of use thereof
EP2704739B1 (en) 2011-05-06 2017-07-12 The Government of the United States of America, as represented by the Secretary of the Department of Health and Human Services Recombinant immunotoxin targeting mesothelin
WO2012162418A1 (en) 2011-05-23 2012-11-29 The University Of North Carolina At Chapel Hill Methods and compositions for heterodimeric targeting ligands
PL397167A1 (pl) 2011-11-28 2013-06-10 Adamed Spólka Z Ograniczona Odpowiedzialnoscia Przeciwnowotworowe bialko fuzyjne
CA2865243A1 (en) 2012-02-23 2013-08-29 President And Fellows Of Harvard College Modified microbial toxin receptor for delivering agents into cells
JP2014021782A (ja) 2012-07-19 2014-02-03 Canon Inc 画像処理装置、その制御方法及びプログラム
EP2740493A1 (en) 2012-12-05 2014-06-11 Institut Curie Conjugates of the B-subunit of Shiga toxin for anticancer therapies
CN111363047A (zh) 2013-03-12 2020-07-03 分子模板公司 用于引起细胞内化的cd20结合免疫毒素及其使用方法
EP2778173A1 (en) 2013-03-15 2014-09-17 Laboratoire Français du Fractionnement et des Biotechnologies Antibody directed against anthrax toxins and its uses
GB2519786A (en) 2013-10-30 2015-05-06 Sergej Michailovic Kiprijanov Multivalent antigen-binding protein molecules
US20160177284A1 (en) 2014-01-27 2016-06-23 Molecular Templates, Inc. Cell-targeted molecules comprising amino-terminus proximal or amino-terminal shiga toxin a subunit effector regions
US20210138076A2 (en) 2014-01-27 2021-05-13 Molecular Templates, Inc. Cell-targeting molecules comprising shiga toxin a subunit effectors and cd8+ t-cell epitopes
US20220401568A1 (en) 2014-01-27 2022-12-22 Molecular Templates, Inc. Cell-targeting molecules comprising shiga toxin a subunit effectors and cd8+ t-cell epitopes
ES2749862T3 (es) 2014-01-27 2020-03-24 Molecular Templates Inc Polipéptidos efectores desinmunizados de subunidad A de toxina Shiga para aplicaciones en mamíferos
JP6814634B2 (ja) 2014-02-05 2021-01-20 モレキュラー テンプレーツ, インク.Molecular Templates, Inc. リボ毒性の一時的な減少に基づき、細胞毒性組換えポリペプチドをスクリーニングし、選択し、同定する方法
ES2864124T3 (es) 2014-03-11 2021-10-13 Molecular Templates Inc Proteínas que comprenden regiones de unión, regiones efectoras de la subunidad A de toxina Shiga y motivos señal de localización de retículo endoplasmático carboxi terminal
US11142584B2 (en) 2014-03-11 2021-10-12 Molecular Templates, Inc. CD20-binding proteins comprising Shiga toxin A subunit effector regions for inducing cellular internalization and methods using same
PT3604333T (pt) 2014-03-11 2021-06-07 Molecular Templates Inc Proteínas compreendendo regiões efetoras da subunidade a da toxina shiga próximas de amino-terminais e regiões de ligação do tipo imunoglobulina de direcionamento celular capazes de se ligarem especificamente a cd38
CN106103416B (zh) 2014-03-14 2021-03-02 拉夸里亚创药株式会社 作为trpm8拮抗剂的氮杂螺衍生物
KR102496206B1 (ko) 2014-06-11 2023-02-06 몰레큘러 템플레이츠, 인코퍼레이션. 프로테아제-절단 저항성의 시가 독소 a 서브유닛 작동체 폴리펩티드 및 이를 포함하는 세포-표적화 분자
CA2951887A1 (en) 2014-06-12 2015-12-17 Cspc Dophen Corporation Homogenous antibody drug conjugates via enzymatic methods
US10550197B2 (en) 2014-06-18 2020-02-04 Chemotherapeutisches Forschungsinstitut Georg-Speyer-Haus CAR-expressing NK-92 cells as cell therapeutic agents
CN105713087B (zh) 2014-11-12 2020-05-08 北京康乐卫士生物技术股份有限公司 人乳头瘤病毒58型单克隆抗体及其应用
WO2016126950A1 (en) 2015-02-05 2016-08-11 Molecular Templates, Inc. Multivalent cd20-binding molecules comprising shiga toxin a subunit effector regions and enriched compositions thereof
KR102357312B1 (ko) 2015-03-04 2022-02-03 아이쥐엠 바이오사이언스 인코포레이티드 Cd20 결합 분자 및 그의 용도
CN114656573B (zh) * 2015-05-30 2024-09-27 分子模板公司 去免疫化的志贺毒素a亚基支架和包含它们的细胞靶向分子
MX2018001208A (es) 2015-07-26 2018-03-26 Molecular Templates Inc Moleculas con direccion a las celulas que comprenden efectores de la subunidad a de la toxina shiga y epitopos de celulas-t cd8+.
CN109195991B (zh) 2016-03-29 2023-10-31 斯特库比股份有限公司 对糖基化pd-l1特异的双重功能抗体及其使用方法
EP3448874A4 (en) 2016-04-29 2020-04-22 Voyager Therapeutics, Inc. COMPOSITIONS FOR TREATING A DISEASE
JP7011657B2 (ja) 2016-10-30 2022-02-10 シャンハイ・ヘンリウス・バイオテック・インコーポレイテッド 抗pd-l1抗体および変異型
MX2019006656A (es) * 2016-12-07 2019-09-09 Molecular Templates Inc Polipeptidos efectores de la sub-unidad a de la toxina shiga andamiajes de los efectores de la toxina shiga y moleculas con direccion hacia las celulas para la conjugacion especifica del sitio.
US11597914B2 (en) 2016-12-26 2023-03-07 Dankook University Cheonan Campus Industry Academic Cooperation Foundation IgG type monoclonal antibodies specifically binding to odontoblast surface
KR102590672B1 (ko) 2017-01-25 2023-10-18 몰레큘러 템플레이츠, 인코퍼레이션. 탈면역된 시가 독소 a 서브유닛 이펙터 및 cd8+ t-세포 에피토프를 포함하는 세포-표적화 분자
JP7201599B2 (ja) 2017-02-28 2023-01-10 中外製薬株式会社 プロテインlを用いたタンパク質精製
LT3592769T (lt) 2017-03-09 2024-08-26 Genmab A/S Antikūnai, atpažįstantys pd-l1
WO2019059400A1 (ja) 2017-09-25 2019-03-28 Jsr株式会社 イムノグロブリン結合タンパク質、及びそれを用いたアフィニティー担体
KR20200143634A (ko) 2018-04-17 2020-12-24 몰레큘러 템플레이츠, 인코퍼레이션. 탈면역된 시가 독소 a 서브유닛 스캐폴드를 포함하는 her2-표적화 분자
WO2020081493A1 (en) 2018-10-16 2020-04-23 Molecular Templates, Inc. Pd-l1 binding proteins
US11713347B2 (en) * 2019-01-23 2023-08-01 Millennium Pharmaceuticals, Inc. CD38-binding proteins comprising de-immunized Shiga toxin A subunit effectors
WO2020154475A1 (en) 2019-01-23 2020-07-30 Molecular Templates, Inc. Proteins comprising modified immunoglobulin variable light chains
WO2021055816A1 (en) 2019-09-18 2021-03-25 Molecular Templates, Inc. Pd-l1 binding molecules comprising shiga toxin a subunit scaffolds
US20220306700A1 (en) 2021-03-17 2022-09-29 Molecular Templates, Inc. Pd-l1 binding proteins comprising shiga toxin a subunit scaffolds and cd8+ t cell antigens

Similar Documents

Publication Publication Date Title
JP2022058385A5 (cg-RX-API-DMAC7.html)
KR101522954B1 (ko) 항체 중쇄불변부위의 이종이중체 고효율 형성을 유도하는 ch3 도메인 변이체 쌍, 이의 제조방법, 및 용도
CN109485734B (zh) 一种靶向bcma和cd19的双特异性嵌合抗原受体及其应用
JP2020513779A5 (cg-RX-API-DMAC7.html)
CN113480657B (zh) 针对her2的单域抗体及其衍生蛋白和应用
US8591893B2 (en) Paratope and epitope of anti-mortalin antibody
JP2023553697A5 (cg-RX-API-DMAC7.html)
JP2023519440A (ja) 多重特異性抗体構築のためのプラットフォーム
JPWO2022224997A5 (cg-RX-API-DMAC7.html)
CN117820479A (zh) 抗il-17a的新型纳米抗体
JP2006521088A (ja) 抗活性化ras抗体
CN117820478B (zh) 纳米抗体的串联分子及其在疾病治疗中的用途
CN117843803B (zh) 串联单域抗体及其在疾病治疗中的应用
KR101963230B1 (ko) 복수개의 단일 항체를 포함하는 단백질 복합체
CN116262786A (zh) 针对folr1的单域抗体及其衍生蛋白和应用
CA3217487A1 (en) Heterodimeric antibodies and antigen-binding fragment thereof
CN108290942B (zh) 与人及小鼠信号素3a交联的抗体及其用途
CN117843777B (zh) 用于炎性疾病治疗的新型纳米抗体及其产品和方法
CN117242086A (zh) 新型蛋白质
CN117866903B (zh) 单域抗体修饰的干细胞及其在疾病治疗中用途
EP3782644A1 (en) Anti-erbb2 single chain antibody, human erbb2-targeting chimeric antigen receptor, recombinant vector, recombinant cell, and application thereof
CN108300725A (zh) 可溶性单链抗体超抗原融合基因及蛋白和其制备与应用
JP6886474B2 (ja) ヒト及びマウスSema3Aに交差結合する抗体及びその用途
JP2017014112A (ja) 抗サバイビン抗体又は抗体誘導体及びそれらの利用
EP3150637A1 (en) Multispecific antibodies